Cellectar Biosciences, Inc. (CLRB): Price and Financial Metrics


Cellectar Biosciences, Inc. (CLRB): $1.54

0.05 (+3.36%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CLRB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CLRB Stock Price Chart Interactive Chart >

Price chart for CLRB

CLRB Price/Volume Stats

Current price $1.54 52-week high $7.90
Prev. close $1.49 52-week low $1.25
Day low $1.48 Volume 32,220
Day high $1.57 Avg. volume 45,029
50-day MA $1.69 Dividend yield N/A
200-day MA $3.56 Market Cap 14.45M

Cellectar Biosciences, Inc. (CLRB) Company Bio


Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is based in Madison, Wisconsin.


CLRB Latest News Stream


Event/Time News Detail
Loading, please wait...

CLRB Latest Social Stream


Loading social stream, please wait...

View Full CLRB Social Stream

Latest CLRB News From Around the Web

Below are the latest news stories about CELLECTAR BIOSCIENCES INC that investors may wish to consider to help them evaluate CLRB as an investment opportunity.

Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer

FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the appointment of Shane Lea as its chief commercial officer, effective November 21, 2022. Mr. Lea brings to Cellectar Biosciences comprehensive commercial leadership experience in hematology and oncology. In his most recent role as senior

Yahoo | November 30, 2022

Cellectar Biosciences (CLRB) Receives a Buy from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on Cellectar Biosciences (CLRB - Research Report) yesterday and set a price target of $7.00. The company's shares opened today at $1.90.According to TipRanks, McCarthy is an analyst with an average return of -37.8% and a 14.69% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and SELLAS Life Sciences Group.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cellectar Biosciences with a $7.67 average price target.

Ryan Adist on TipRanks | November 22, 2022

Cellectar Biosciences Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference

Preclinical data demonstrate ability to deliver targeted alpha-emitting isotopes to malignant cells and therapeutic efficacyFLORHAM PARK, N.J., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the presentation of preclinical data at the 13th Annual World ADC Conference supporting development of CLR 12120 ser

Yahoo | November 21, 2022

Cellectar Announces Resolution of Breach of Contract and Intellectual Property Dispute

Secures license to the patents at issue in the lawsuitFLORHAM PARK, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced that Cellectar Biosciences, Inc., Wisconsin Alumni Research Foundation, and Drs. Jamey Weichert and Anatoly Pinchuk have resolved a lawsuit filed by Cellectar in October 2021 in the United States Di

Yahoo | November 16, 2022

Cellectar Biosciences (CLRB) Investor Presentation - Slideshow (NASDAQ:CLRB)

The following slide deck was published by Cellectar Biosciences, Inc.

Seeking Alpha | November 4, 2022

Read More 'CLRB' Stories Here

CLRB Price Returns

1-mo -3.75%
3-mo -26.67%
6-mo -60.71%
1-year -70.38%
3-year -94.38%
5-year -98.75%
YTD -9.94%
2022 -74.25%
2021 -68.08%
2020 -7.56%
2019 45.16%
2018 -88.69%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6132 seconds.